touchPODCAST

touchPODCAST

By touchpodcastScience
Download on the App Store

touchPODCAST episodes

  • Shaping ART around individual needs: Maximizing adherence and quality of life

    touchPANEL DISCUSSION for touchINFECTIOUS DISEASES

    Listen to a panel of experts discuss the importance of optimizing antiretroviral therapy through an individualized approach to care and shared decision making. 

    The experts

    • Prof Jens Lundgren, University of Copenhagen, Hvidovre, Denmark
  • Prof Marta Boffito, Chelsea and Westminster Hospital and Imperial College London, UK
  • Ms Angelina Namiba, 4M Network, UK

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from Viiv Healthcare. This activity is provided by touchIME. 

    For further information visit:

    https://touchinfectiousdiseases.com/

    39 min
  • Latest developments in neuromyelitis optica spectrum disorder (NMOSD): Diagnostics, treatments and patient-centered care

    touchSATELLITE SYMPOSIUM for touchOPHTHALMOLOGY

    Listen to this touch satellite symposium recorded live in June 2023 at the Annual Meeting of the Consortium of Multiple Sclerosis Centers.

    Dr Dalia Rotstein (Canada), the chair for the symposium, is joined by Dr Eoin Flanagan (USA) and Dr Jeffrey Bennett (USA).

    The first session, led by Dr Eoin Flanagan (03:55), focuses on the characterization of NMOSD, and the latest evidence-based strategies to achieve timely and accurate diagnosis. This is followed by audience Q&A (12:38).

    The second session, led by Dr Jeffrey Bennett (15:57), discusses the latest efficacy and safety data on immunotherapies for NMOSD, and the factors influencing clinical decision making in daily practice. This is followed by audience Q&A (30:48).

    In the third session, Dr Dalia Rotstein (34:49) summarizes the wider clinical symptoms of NMOSD and multidisciplinary strategies to mitigate the burden of disease. This is followed by a panel discussion in which the faculty provide their insights on selected Q&A from the audience (39:30).

    This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Alexion. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchophthalmologyime.org/nmosd-latest-developments/

    51 min
  • Latest developments in neuromyelitis optica spectrum disorder (NMOSD): Diagnostics, treatments and patient-centered care

    touchSATELLITE SYMPOSIUM for touchNEUROLOGY

    Listen to this touch satellite symposium recorded live in June 2023 at the Annual Meeting of the Consortium of Multiple Sclerosis Centers.

    Dr Dalia Rotstein (Canada), the chair for the symposium, is joined by Dr Eoin Flanagan (USA) and Dr Jeffrey Bennett (USA).

    The first session, led by Dr Eoin Flanagan (03:55), focuses on the characterization of NMOSD, and the latest evidence-based strategies to achieve timely and accurate diagnosis. This is followed by audience Q&A (12:38).

    The second session, led by Dr Jeffrey Bennett (15:57), discusses the latest efficacy and safety data on immunotherapies for NMOSD, and the factors influencing clinical decision making in daily practice. This is followed by audience Q&A (30:48).

    In the third session, Dr Dalia Rotstein (34:49) summarizes the wider clinical symptoms of NMOSD and multidisciplinary strategies to mitigate the burden of disease. This is followed by a panel discussion in which the faculty provide their insights on selected Q&A from the audience (39:30).

    This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Alexion. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchneurologyime.org/nmosd-latest-developments/ 

    51 min
  • Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practice

    touchPANEL DISCUSSION for touchHAEMATOLOGY

    Listen to a panel of leading experts discuss the key considerations for treatment selection and sequencing in patients with RRMM.

    The experts:

    • Dr Sarah Holstein, University of Nebraska Medical Center, Omaha, NE, USA
  • Dr Nikhil Munshi, Dana-Farber Cancer Institute, Boston, MA, USA
  • Dr Noopur Raje, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME.

    For further information please visit: https://touchhaematologyime.org/

     

    40 min
  • Key considerations for treatment selection and sequencing in patients with RRMM Lessons from real-life clinical practice

    touchPANEL DISCUSSION for touchONCOLOGY 

    Listen to a panel of leading experts discuss the key considerations for treatment selection and sequencing in patients with RRMM.

    The experts:

    • Dr Sarah Holstein, University of Nebraska Medical Center, Omaha, NE, USA
  • Dr Nikhil Munshi, Dana-Farber Cancer Institute, Boston, MA, USA
  • Dr Noopur Raje, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME.

    For further information please visit: https://touchoncology.com/

     

    40 min
  • Individualizing long-term treatment and care in active MS

    touchIN CONVERSATION for touchNEUROLOGY

    Listen to Dr Ruth Dobson (Queen Mary University of London, UK) in conversation with Dr Ide Smets (MS Center ErasMS, Rotterdam, The Netherlands). They discuss questions submitted by the healthcare professional (HCP) audience and provide their expert insights on the practicalities of therapeutic sequencing options in multiple sclerosis (MS).


    Clinical themes:

    1. Factors guiding the use of high-efficacy disease-modifying therapies (DMTs) in the management of active MS (02:01)
  • Current approaches and safety considerations relating to DMT switching and sequencing in MS (14:17)
  • Approaches needed to support women of child-bearing age living with MS through family planning and beyond (23:38)

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: www.touchneurology.com/individualizing-long-term-treatment-and-care-in-MS/

    37 min
  • MDT perspectives on approaches for the use of immune checkpoint inhibitor therapy in patients with solid tumours

    touchMDT for touchONCOLOGY

    Listen to key experts from a multidisciplinary team evaluate the strategies for identifying and monitoring immune-related adverse events.

    The multidisciplinary team:

    • Medical oncologist: Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan
  • Oncology nurse: Ms Tara Hurley, Royal Marsden NHS Foundation Trust, Sutton, UK
  • Clinical oncology pharmacist: Dr Alison Palumbo, Oregon Health and Science University, Oregon, USA

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from MSD. This activity is jointly provided by USF Health and touchIME.


    For further information visit our website: https://touchoncologyime.org/immune-checkpoint-inhibitors-in-solid-tumours/

     

    12 min
  • MDT perspectives on the role of biomarkers in informing immune checkpoint inhibitor use across tumour types

    touchMDT for touchONCOLOGY

    Listen to key experts from a multidisciplinary team review the role of biomarkers in informing immune checkpoint inhibitor use across tumour types.

    The multidisciplinary team

    • Medical oncologist: Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan
  • Pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Heidelberg, Germany

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from MSD. This activity is jointly provided by USF Health and touchIME.


    For further information visit our website: https://touchoncologyime.org/immune-checkpoint-inhibitors-in-solid-tumours/

     

    13 min
  • MDT perspectives on strategies for identifying and monitoring immune-related adverse events

    touchMDT for touchONCOLOGY

    Listen to key experts from a multidisciplinary team evaluate the strategies for identifying and monitoring immune-related adverse events.

    The multidisciplinary team:

    • Medical oncologist: Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan
  • Oncology nurse: Ms Tara Hurley, Royal Marsden NHS Foundation Trust, Sutton, UK
  • Clinical oncology pharmacist: Dr Alison Palumbo, Oregon Health and Science University, Portland, OR, USA

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from MSD. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchoncologyime.org/immune-checkpoint-inhibitors-in-solid-tumours/

     

    13 min
  • MDT perspectives on indications for immune checkpoint inhibitors in patients with solid tumours

    touchMDT for touchONCOLOGY

    Listen to key experts from a multidisciplinary team discuss the current and upcoming indications for immune checkpoint inhibitors in patients with solid tumours and review general considerations for their use.

    The multidisciplinary team:

    • Medical oncologist: Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan
  • Oncology nurse: Ms Tara Hurley, Royal Marsden NHS Foundation Trust, Sutton, UK

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from MSD. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchoncologyime.org/immune-checkpoint-inhibitors-in-solid-tumours/

     

    14 min

About touchPODCAST

From the publisher's feed

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.